This is a well-performed analysis of the effect of sibling allograft for aplastic anaemia. The analysis is using the "Donor/No Donor" analysis proposed by Gray and Wheatley. This method, and its limitations, could be better described here. It compares patients with a donor with those with no donor. It doesn't compare sibling allograft with no sibling allograft. It is important that the compliance with transplant is given here. How many of the "donor" patients were transplanted -some may not have been for various reasons. Additionally, this method looks only at matched sibling allograft -matched unrelated donor would be in the no donor group, and the assumption here is that most patients with donors get allografts now, rather than after progression, and that there are very few alternative transplants performed, or those that are are of limited value. The limitations in the modern era of this approach in AML (its original setting) are well known and require some rehearsing here. In particular, the arms should be called donor vs no donor not SCT vs not.
First, sibling, related, or unrelated donors constitute a heterogeneous pool. In the past, survival differed considerably among those groups. We intended from the start to reduce heterogeneity by confining to sibling donors. Second, we tried to keep information about 'Mendelian randomization' as short as possible and we refered to two papers that are best suited to explain the principles behind this specific concept.
We want to take up the suggestion of the reviewer to broaden the text by providing more explanagory information about this method. Therefore, we added the following section in the method chapter: We want to address a quote from the reference: Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 1991;7(Suppl 3):9-12. "The value of allogeneic BMT can, however, be assessed unbiasedly using 'Mendelian randomisation', i.e. comparing patients whose siblings are HLA-compatible with those who are not."
Principle of 'Mendelian randomization' There are ethical concerns around randomization of patients with severe aplastic anemia to transplantation versus non-transplantation. In general, MSD-HSCT is a life-threatening treatment that can lead to early severe adverse events including death. Gray 1991 and Wheatley 2004 described the potential of 'Mendelian randomization' to minimize bias when comparing MSD-HSCT with an alternative therapy. The base concept has been ascribed to Katan 1986. 'Mendelian randomization' means the view that nature itself has already 'randomized' the paternal and
We also want to address a quote from reference: Wheatley K, Gray R. Commentary: Mendelian randomization: an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol 2004; 33:15-17 . "Thus, we need an alternative, unbiased method for evaluating SCT. The answer is provided by Mendelian, or genetic, randomization. [...] In the haematological context, for a patient's sibling to be a suitable donor, he/she must have inherited the same tissue type as the patient from their mother and father. Since the chances of there being a match depend on the random assortment of genes at fertilization, only one in four siblings will be expected to have the same tissue type as the patient. Thus, whether or not a patient has a matched sibling donor available is essentially a random process and the presence or absence of a donor can be used as a surrogate for randomization." Additionally, given that the outcome is OS, I'm not sure how high the risk of bias is from not blinding -death is a pretty objective endpoint.
We agree with the reviewer.
We added the following sentences with respect to risk of bias to the section 'Characteristics of included articles': We judged a low risk of bias for blinding the assessment of overall mortality. Blinding or lack of blinding is not expected to make a difference concerning overall mortality.
Please therefore analyse as donor vs no donor (to remove selection and zero timeshift biases) and give compliance levels -what transplants were
We would like to refer to our response expressed in the first row.
performed.
Reviewer #3: comment to Author Jacqueline Milton, Boston University, USA Response by author 1. This study examined subjects with ages ranging from early childhood to adulthood. The discussion describes a variety to studies in which patients younger than 40 years of age had 75% to 90% change of long-term cure with allogeneic bone marrow transplantation and a three to five year survival rate between 75% and 95% in younger patients. Is there reason to believe that age may be confounding the association treatment (transplantation vs. immunosuppressive therapy) and mortality?
Some guidelines recommended to offer transplantation only to patients younger than 40 years of age. Allogeneic transplantation is a physical demanding treatment and it was assumed that the physical fitness in younger patients is better in older patients and that the survival depends upon physical resistance against the physical stress. Guidelines set a cut-off at 40 years to specify a decision point in an decision tree to find the optimal individual treatment. Some have questioned a strict age cut-off and recommended to acknowledge whether a patient has the required physical fitness to survive the treatment including also patients older than 40 years. According to Gupta et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica. 2010 Dec;95(12):2119-25: "Mortality risks increased with age. Risks were also higher in patients with a poor performance score." Age is certainly a confounder especially concerning overall mortality as the primary outcome. We want to indicate to the following text in the manuscript:
We judged studies as consistent with the principle of 'Mendelian randomization' if all transplant donors were clearly siblings and if the allocation of patients to treatment groups was not based on age. We regarded studies as not consistent with the principle of 'Mendelian randomization' if age was not balanced between groups, indicating that age played a role in the group assignment. Example for imbalance: distribution of age categories was statistically not comparable (P value less than 0.05).
2. The authors combined those undergoing immunosuppressive therapy as comparator with either 1)antithymocyte, 2)antilyphocyte or 3) a combination of the two. Is there any evidence of a difference in outcome between these 3 methods?
We included IST as comparator with either antithymocyte/¬antilymphocyte globulin or ciclosporin or a combination of the two. That means ATG alone or ATG in combination with ciclosporin or ALG alone or ALG in combination with ciclosporin.
We have tried to clarify the composition of immunosuppressive therapy and we added explanations of each component. 
GENERAL COMMENTS
The Mendelian approach of Gray & Wheatley (1991) clearly refers to a donor vs no donor comparison, and indeed if you look at the work of both authors, especially Keith Wheatley and the AML cooperative group, the comparison of transplant is in a donor vs no donor fashion. This shows the concept of compliance is important herewhat proportion of patients with a matched sibling donor get a sib allograft. This is missing from the paper, and is absolutely crucial. As Wheatley points out in another paper, low compliance gives an artificially precise estimate of a diluted treatment effect. If only 10% of patients get SCT, for example, then o-e is divided by 10, but V is unaltered meaning that the confidence intervals are tight around no effect.
We also need to know how many patients in the no donor group got a MUD SCT; and whether sibling allograft was given upfront or reserved for salvage.
Please also call the arms donor vs no donor as they are not allograft vs not, because of the compliance issue addressed above.
I am unclear of the ethical reasons surrounding randomisation to SCT vs not. It is done for autograft in other diseases with poor prognosis, and has been tried for allograft as well. The ethical issues peculiar to this condition need to be made explicit here.
The tweaks requested here will address the shortcomings in the bullet point questions above.
VERSION 2 -AUTHOR RESPONSE
Reviewer #1: comment to Author Seiji Kojima MD,PhD; School of Medicine, Nagoya, Japan
Response by author
The authors tried to evaluate the effectiveness and adverse events of first alloSCT and IST in patients with severe aplastic anemia by metaanalysis. However, only 3 trials satisfied the criteria and total number of patients were too small ,only 302 patients. Moreover, all data were collected 15 to 30 years ago. The treatments were out of date. The results may cause misleading for modern practice.
The findings result from the available study data. We want to address a quote from the reference: Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 1991;7(Suppl 3):9-12. "The value of allogeneic BMT can, however, be assessed unbiasedly using 'Mendelian randomisation', i.e. comparing patients whose siblings are HLA-compatible with those who are not."
We also want to address a quote from reference: Wheatley K, Gray R. Commentary: Mendelian randomization: an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol 2004; 33:15-17 . "Thus, we need an alternative, unbiased method for evaluating SCT. The answer is provided by Mendelian, or genetic, randomization. [...] In the haematological context, for a patient's sibling to be a suitable donor, he/she must have inherited the same tissue type as the patient from their mother and father. Since the chances of there being a match depend on the random assortment of genes at fertilization, only one in four siblings will be expected to have the same tissue type as the patient. Thus, whether or not a patient has a matched sibling donor available is essentially a random process and the presence or absence of a donor can be used as a surrogate for randomization."
Additionally, given that the outcome is OS, I'm not sure how high the risk of bias is from not blinding -death is a pretty objective endpoint.
We added the following sentences with respect to risk of bias to the section 'Characteristics of included articles':
We judged a low risk of bias for blinding the assessment of overall mortality. Blinding or lack of blinding is not expected to make a difference concerning overall mortality.
performed.
Reviewer #3: comment to Author Jacqueline Milton, Boston University, USA
Response by author 1. This study examined subjects with ages ranging from early childhood to adulthood. The discussion describes a variety to studies in which patients younger than 40 years of age had 75% to 90% change of long-term cure with allogeneic bone marrow transplantation and a three to five year survival rate between 75% and 95% in younger patients. Is there reason to believe that age may be confounding the association treatment (transplantation vs. immunosuppressive therapy) and mortality?
Some guidelines recommended to offer transplantation only to patients younger than 40 years of age. Allogeneic transplantation is a physical demanding treatment and it was assumed that the physical fitness in younger patients is better in older patients and that the survival depends upon physical resistance against the physical stress. Guidelines set a cut-off at 40 years to specify a decision point in an decision tree to find the optimal individual treatment. Some have questioned a strict age cut-off and recommended to acknowledge whether a patient has the required physical fitness to survive the treatment including also patients older than 40 years. We would like to point to some statements in seminal articles. 
